About the Speaker
Christine Dufès is a Senior Lecturer at the Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow (United Kingdom). She obtained a Doctorate in Pharmacy (with Distinction and congratulations of the Jury) and a PhD (with a European Label, Distinction and congratulations of the Jury) from the University of Poitiers (France). After four years as a post-doctoral researcher at the Cancer Research UK Beatson Laboratories in Glasgow, she was appointed as a Lecturer at the Strathclyde Institute of Pharmacy and Biomedical Sciences in 2006 and became a Senior Lecturer in 2012. Abstract
The possibility of using genes as medicines to treat cancer is limited by the lack of safe and efficacious delivery systems able to deliver therapeutic genes selectively to tumours by intravenous administration, without secondary effects to healthy tissues. In order to remediate to this problem, we investigated if the conjugation of the polypropylenimine dendrimer to transferrin, whose receptors are overexpressed on numerous cancers, could result in a selective gene delivery to tumours after intravenous administration, leading to an increased therapeutic efficacy. The objectives of this study are to evaluate the targeting and therapeutic efficacies of a novel transferrin-bearing polypropylenimine dendrimer. The intravenous administration of transferrin-bearing polypropylenimine polyplex resulted in gene expression mainly in the tumours. Consequently, the intravenous administration of the delivery system complexed to a therapeutic DNA encoding TNF led to a rapid and sustained tumour regression over one month (90% complete response, 10% partial response on A431 human epidermoid tumours). It also resulted in tumour suppression for 60% of PC-3 and 50% of DU145 prostate tumours. The treatment was well tolerated by the animals, with no apparent signs of toxicity. Transferrin-bearing polypropylenimine is therefore a highly promising delivery system for cancer therapy.
Tumour Regression after Intravenous Administration of Novel Tumour-targeted Nanomedicines
Video Jul 22, 2014
About the Speaker
LC-MS/MS for Bioanalytical Peptide and Protein Quantification: MS ConsiderationsVideo
Caitlin Dunning, Associate Scientist, discusses how to use mass spectrometry to develop sensitive, selective, and robust quantification methods for peptide and protein quantification, including: basic mass spectrometry considerations, MS tuning, and best practices for success.WATCH NOW
Targeting Tumors: Challenges of Antibody-Drug ConjugatesVideo
More than two dozen ADCs are currently being used in the clinic to treat diseases like Hodgkin's lymphoma and breast cancer, and researchers are developing many more. But it's taken decades to find the right combination of drug, antibody target and linker, and then make sure the right amount of ADC hits the tumor.
How One Scientist Averted a National Health CrisisVideo
In 1960, Frances Kelsey was one of the Food and Drug Administration’s newest recruits. Before the year was out, she would begin a fight that would save thousands of lives — though no one knew it at the time.WATCH NOW
Comments | 0 ADD COMMENT
27th International Conference on Nanomedicine and Nanomaterials
Oct 18 - Oct 19, 2018